{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:22:13Z","timestamp":1794871333037,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>The TWO Study (Transplantation Without Overimmunosuppression) aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients, using a delayed infusion protocol at 6 mo posttransplant to promote a Treg-skewed lymphocyte repopulation after alemtuzumab induction. We hypothesized that this would allow safe weaning of immunosuppression to tacrolimus alone. The COVID-19 pandemic led to the suspension of alemtuzumab use, and therefore, we report the unique cohort of 7 patients who underwent the original randomized controlled trial protocol. This study presents a unique insight into Treg therapy combined with alemtuzumab and is therefore an important proof of concept for studies in other diseases that are considering lymphodepletion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Living donor kidney transplant recipients were randomized to receive autologous polyclonal Treg at week 26 posttransplantation, coupled with weaning doses of tacrolimus, (Treg therapy arm) or standard immunosuppression alone (tacrolimus and mycophenolate mofetil). Primary outcomes were patient survival and rejection-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Successful cell manufacturing and cryopreservation until the 6-mo infusion were achieved. Patient and transplant survival was 100%. Acute rejection-free survival was 100% in the Treg-treated group at 18 mo after transplantation. Although alemtuzumab caused a profound depletion of all lymphocytes, including Treg, after cell therapy infusion, there was a transient increase in peripheral Treg numbers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>The study establishes that delayed autologous Treg therapy is both feasible and safe, even 12 mo after cell production. The findings present a new treatment protocol for Treg therapy, potentially expanding its applications to other indications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005065","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:01:32Z","timestamp":1717718492000},"page":"2278-2286","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation"],"prefix":"10.1097","volume":"108","author":[{"given":"Matthew O.","family":"Brook","sequence":"first","affiliation":[{"name":"Oxford Transplant Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom."},{"name":"Translational Research Immunology Group, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Translational Research Immunology Group, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Hester","sequence":"additional","affiliation":[{"name":"Translational Research Immunology Group, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Hammad","sequence":"additional","affiliation":[{"name":"Peter Gorer Department of Immunobiology, School of Immunology and Microbial Science, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Alzhrani","sequence":"additional","affiliation":[{"name":"Translational Research Immunology Group, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Rombach","sequence":"additional","affiliation":[{"name":"Peter Gorer Department of Immunobiology, School of Immunology and Microbial Science, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dutton","sequence":"additional","affiliation":[{"name":"Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Peter Gorer Department of Immunobiology, School of Immunology and Microbial Science, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Wood","sequence":"additional","affiliation":[{"name":"Translational Research Immunology Group, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Friend","sequence":"additional","affiliation":[{"name":"Oxford Transplant Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Harden","sequence":"additional","affiliation":[{"name":"Oxford Transplant Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Issa","sequence":"additional","affiliation":[{"name":"Translational Research Immunology Group, University of Oxford, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semnephrol.2018.02.008","article-title":"Cardiovascular disease after kidney transplant.","volume":"38","author":"Rao","year":"2018","journal-title":"Semin Nephrol"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients.","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/tri.13789","article-title":"Cellular therapies in organ transplantation.","volume":"34","author":"Hoogduijn","year":"2021","journal-title":"Transpl Int"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.humimm.2017.12.013","article-title":"Regulatory T cells for tolerance.","volume":"79","author":"Kawai","year":"2018","journal-title":"Hum Immunol"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.it.2021.11.001","article-title":"Towards regulatory cellular therapies in solid organ transplantation.","volume":"43","author":"Bottomley","year":"2022","journal-title":"Trends Immunol"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A rapamycin-based GMP\u2014compatible process for the isolation and expansion of regulatory T cells for clinical trials.","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"750286","DOI":"10.3389\/fcell.2021.750286","article-title":"Freezing medium containing 5% DMSO enhances the cell viability and recovery rate after cryopreservation of regulatory T cell products ex vivo and in vivo.","volume":"9","author":"Kaiser","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials.","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/ajt.15700","article-title":"Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation.","volume":"20","author":"S\u00e1nchez-Fueyo","year":"2020","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fimmu.2018.00354","article-title":"Cell therapy in organ transplantation: our experience on the clinical translation of regulatory T cells.","volume":"9","author":"Safinia","year":"2018","journal-title":"Front Immunol"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"m3734","DOI":"10.1136\/bmj.m3734","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial.","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/ajt.16395","article-title":"Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.","volume":"21","author":"Harden","year":"2021","journal-title":"Am J Transplant"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.","volume":"384","author":"Haynes","year":"2014","journal-title":"Lancet"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"e061864","DOI":"10.1136\/bmjopen-2022-061864","article-title":"Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.","volume":"12","author":"Brook","year":"2022","journal-title":"BMJ Open"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/TP.0b013e3181661695","article-title":"Influence of time of rejection on long-term graft survival in renal transplantation.","volume":"85","author":"Opelz","year":"2008","journal-title":"Transplantation"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-1-0716-2647-4_14","article-title":"A GMP protocol for the manufacture of Tregs for clinical application.","volume":"2559","author":"O\u2019Neil","year":"2023","journal-title":"Methods Mol Biol"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1016\/S2468-2667(21)00200-0","article-title":"COVID-19 pandemic and worldwide organ transplantation: a population-based study.","volume":"6","author":"Aubert","year":"2021","journal-title":"Lancet Public Health"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S0140-6736(20)31040-0","article-title":"Organ procurement and transplantation during the COVID-19 pandemic.","volume":"395","author":"Loupy","year":"2020","journal-title":"Lancet"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1172\/JCI39922","article-title":"Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.","volume":"120","author":"Sagoo","year":"2010","journal-title":"J Clin Invest"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1111\/ajt.13480","article-title":"Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients.","volume":"15","author":"Newell","year":"2015","journal-title":"Am J Transplant"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1172\/JCI39933","article-title":"Identification of a B cell signature associated with renal transplant tolerance in humans.","volume":"120","author":"Newell","year":"2010","journal-title":"J Clin Invest"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1097\/01.tp.0000239268.64408.84","article-title":"Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.","volume":"82","author":"Trzonkowski","year":"2006","journal-title":"Transplantation"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants.","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/ajt.14619","article-title":"Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study)\u2014results of a randomized controlled clinical trial.","volume":"18","year":"2018","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:01:07Z","timestamp":1749045667000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005065","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}